CClinicalTrials.gg
CompletedNCT05842642Updated Sep 18, 2023

Effects of Adding an Oculomotor Therapy Treatment in Patients With Migraine

An interventional study of Cervical and Oculomotor in Migraine, sponsored by University of Jaén. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by University of Jaén · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Headaches are the fourth cause/reason for disability in the world population. Of which, headache in general accounts for 47%, 38% are tension headaches, 10% migraines and 3% for chronic headache lasting more than 15 days a month.

Migraine is a neurological disease/disorder originating in the central nervous system with difficulty modulating responses to common sensory stimuli.

Different studies have linked possible oculomotor problems and headaches, being an important and complex relationship.

It is difficult to find a suitable and beneficial treatment for the treatment of migraine. It is hypothesized that adding a treatment of manual therapy and therapeutic exercise of the oculomotor system to an already established protocol of manual therapy and therapeutic exercise of the cervical region, has an additional benefit for patients with migraines (in relation to the quality of life, symptomatology and functionality).

Read the detailed description

Migraine is a neurological disease/disorder originating in the central nervous system with difficulty modulating responses to common sensory stimuli. It is characterized by being unilateral, frontotemporal, pulsatile, of moderate or severe intensity, nausea and/or vomiting, sensitivity to movement, visual, auditory, and other afferent stimuli may appear. In addition, other symptoms such as fatigue, neck stiffness, decreased concentration, mood swings and yawning may appear, and the headache may be anticipated up to 48 hours.

It has been hypothesized that the possible relationship between the eyes and the pathophysiology of migraine is due to the trigeminal-cervical complex, since if there is an alteration it would be established by a nociceptive impulse that can trigger central sensitization in the trigeminal nuclei.

Today, the quintessential treatment is pharmacological where the excessive use of medications can trigger possible side effects such as depression, anxiety, weight gain, fatigue and drowsiness, among others, causing an alteration in the patient's quality of life more than of the migraine attack.

Several studies show that there are other non-pharmacological treatment options such as manual physiotherapy and therapeutic exercise for migraines, and that it is effective for reducing the intensity and frequency of attacks, the use of medication and improving the quality of life. Being preventive treatments in order to avoid the frequency and intensity of these attacks.

At present, the role of oculomotricity in headache, although it may be promising, has not been extensively studied. In the literature that the investigators have reviewed, the investigators have found very few studies that investigate manual therapy directly on the eyeball, despite the great relationship of the trigeminal-vascular nerve with migraines and how it influences the different variables.

The main objective of the present study is to investigate the impact and possible additional benefits of adding an oculomotor treatment to a manual therapy protocol of the cervical region in patients with migraine.

02

Conditions studied

  • Migraine

Browse trials for

Keywords

  • migraine
  • oculomotor
  • manual therapy
  • cervical
03

In context

Migraine Disorders

1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.

This study's enrollment of 32 is below the median of 80 across 1,175 interventional studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

University of Jaén is the lead sponsor of 79 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 18-65 years
  • Suffer less than 15 days of headache per month,
  • The pain must have these characteristics: unilateral, pulsating, of moderate to severe intensity, during the attack, nausea and/or vomiting, with the possible presence of an aura
  • History of evolution of more than a year,
  • Onset and aggravation in the afternoon and
  • Relation to visual work
  • Feeling of eye discomfort,
  • Photophobia
  • Neck pain after attack.

Exclusion criteria

Exclusion Criteria:

  • Receiving some type of preventive physiotherapy treatment at the time of the intervention
  • Subjects with preventive medication, pregnancy or lactation, with neurological, systemic or psychiatric disorders, suffering from bone degeneration
  • Metabolic or musculoskeletal problems that could imply risk of the vertebral artery
  • Dizziness
  • Unbalanced tension
  • Use of specific medication
  • Lack of fluency in Spanish.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (actual)

Study arms

  • Placebo comparator
    Cervical treatment

    A treatment of the cervical region will be done for 6 weeks, once a week, and they will be taught exercises to do at home.

    Other: Cervical

  • Experimental
    Oculomotor treatment

    An oculomotor treatment will be added to the treatment of the cervical group with specific exercises in the area. Once a week during 6 weeks

    Other: Cervical · Other: Oculomotor

Interventions

  • OtherCervical

    6 weeks of treatment

  • OtherOculomotor

    6 weeks of treatment

06

What researchers measure

Primary outcomes

  1. Changes in the impact

    Using the Headache Impact Test (HIT-6) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

Secondary outcomes

  1. Changes in the pain

    Using the Visual Analog Scale (VAS). Each item is scored 0-10 (0= no pain; 10= the major pain that the patient can imagine) yielding a total between 0 and 10.

    Time frame: Baseline, 6 weeks and 3 months after intervention

  2. Changes in the disability

    Using the Migraine Disability Assessment (MIDAS) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  3. Changes in the depression

    Using the Patient Health Questionnaire (PHQ-9) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  4. Changes in the anxiety

    Using the Generalized Anxiety Disorder (GAD-7) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  5. Changes in the sleep quality

    Using the Pittsburgh Sleep Quality Index (PSQI) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  6. Changes in the kinesiophobia

    Using the Tampa Scale of Kinesiophobia (TSK-11) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  7. Changes in the catastrophizing

    Using the Pain Catastrophizing Scale (PCS) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  8. Changes in the central sensitization

    Using the Central Sensitization Inventory (CSI) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  9. Changes in the neck disability

    Using the Neck Disability Index (NDI) Questionnaire

    Time frame: Baseline, 6 weeks and 3 months after intervention

  10. Changes in the head repositioning

    Using the Head Repositioning. This test will be used to assess the subject's proprioceptive ability to reposition the head on the trunk in the horizontal and sagittal planes and to measure the impact of treatment techniques. The distance between the center of the objective (target) and the laser point is measured, representing the cervico-cephalic positioning error

    Time frame: Baseline, 6 weeks and 3 months after intervention

  11. Changes in the strength of the deep cervical flexors

    Using the Grimmer Test

    Time frame: Baseline, 6 weeks and 3 months after intervention

  12. Changes in the ocular movement

    Using Smooth tracking test. It consists of following with the eyes an object (stick with a painted dot) that moves in the shape of an "H".

    Time frame: Baseline, 6 weeks and 3 months after intervention

  13. Changes in the ocular movement with variation of the head

    Using the Smooth Pursuit Neck Torsion. It consists of following with the eyes an object (stick with a painted dot) that moves in the shape of an "H" with variant head position

    Time frame: Baseline, 6 weeks and 3 months after intervention

  14. Changes in the range of movement

    Using the Cervical Range of Motion Instrument

    Time frame: Baseline, 6 weeks and 3 months after intervention

  15. Changes in the quality of life

    Using the Short-Form 12 Health Survey (SF-12). Composed of twelve items, eight dimensions (physical function, physical role, bodily pain, mental health, general health, vitality, social function, and emotional role). The score ranges from 0 to 100, where the higher score implies a better health-related quality of life.

    Time frame: Baseline, 6 weeks and 3 months after intervention

07

Study locations

1 site
  • Physiotherapy clinic
    Madrid, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05842642
Lead sponsor
University of Jaén
Responsible party
Alexander Achalandabaso (Clinical Professor, University of Jaén) — Principal investigator
First posted
May 6, 2023
Start date
Apr 3, 2023
Primary completion
May 30, 2023
Completion
Sep 15, 2023
Last update
Sep 18, 2023

Study contacts

Alexander Achalandabaso, PhD
study director · University of Jaen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion